# Tenon Medical, Inc.: financial statements, quarterly

TNON · Nasdaq · CIK 1560293 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tnon.md) · [Financials](/companies/tnon/financials.md) · [Filings](/companies/tnon/filings.md) · [Insiders](/companies/tnon/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tnon/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [944](/filings/0001213900-24-098375.md) | [808 d](/filings/0001013762-25-002734.md) | [719](/filings/0001213900-25-042714.md) | [901](/filings/0001213900-25-075652.md) | [887](/filings/0001213900-25-109961.md) | [770 d](/filings/0001213900-26-035707.md) | [726](/filings/0001213900-26-057695.md) | [564](/filings/0001213900-26-089258.md) | [1,173](/filings/0001213900-25-109961.md) | [1,481 d](/filings/0001213900-26-035707.md) | [1,379](/filings/0001213900-26-057695.md) | [1,279](/filings/0001213900-26-089258.md) |
| Cost of revenue | $k | [409](/filings/0001213900-24-098375.md) | [249 d](/filings/0001013762-25-002734.md) | [249](/filings/0001213900-25-042714.md) | [431](/filings/0001213900-25-075652.md) | [469](/filings/0001213900-25-109961.md) | [417 d](/filings/0001213900-26-035707.md) | [403](/filings/0001213900-26-057695.md) | [319](/filings/0001213900-26-089258.md) | [400](/filings/0001213900-25-109961.md) | [464 d](/filings/0001213900-26-035707.md) | [434](/filings/0001213900-26-057695.md) | [465](/filings/0001213900-26-089258.md) |
| Gross profit | $k | [535](/filings/0001213900-24-098375.md) | [559 d](/filings/0001013762-25-002734.md) | [470](/filings/0001213900-25-042714.md) | [470](/filings/0001213900-25-075652.md) | [418](/filings/0001213900-25-109961.md) | [353 d](/filings/0001213900-26-035707.md) | [323](/filings/0001213900-26-057695.md) | [245](/filings/0001213900-26-089258.md) | [773](/filings/0001213900-25-109961.md) | [1,017 d](/filings/0001213900-26-035707.md) | [945](/filings/0001213900-26-057695.md) | [814](/filings/0001213900-26-089258.md) |
| Research and development | $k | [737](/filings/0001213900-24-098375.md) | [691 d](/filings/0001013762-25-002734.md) | [669](/filings/0001213900-25-042714.md) | [708](/filings/0001213900-25-075652.md) | [657](/filings/0001213900-25-109961.md) | [569 d](/filings/0001213900-26-035707.md) | [691](/filings/0001213900-26-057695.md) | [503](/filings/0001213900-26-089258.md) | [428](/filings/0001213900-25-109961.md) | [527 d](/filings/0001213900-26-035707.md) | [662](/filings/0001213900-26-057695.md) | [768](/filings/0001213900-26-089258.md) |
| Operating income | $k | [(3,378)](/filings/0001213900-24-098375.md) | [(3,141) d](/filings/0001013762-25-002734.md) | [(3,506)](/filings/0001213900-25-042714.md) | [(3,872)](/filings/0001213900-25-075652.md) | [(3,215)](/filings/0001213900-25-109961.md) | [(3,173) d](/filings/0001213900-26-035707.md) | [(3,677)](/filings/0001213900-26-057695.md) | [(2,857)](/filings/0001213900-26-089258.md) | [(3,392)](/filings/0001213900-25-109961.md) | [(2,866) d](/filings/0001213900-26-035707.md) | [(3,280)](/filings/0001213900-26-057695.md) | [(3,354)](/filings/0001213900-26-089258.md) |
| Interest expense | $k | [4.0](/filings/0001213900-23-087015.md) | [17.0 d](/filings/0001213900-24-028010.md) | [34.0](/filings/0001213900-24-043085.md) | [0.0 d](/filings/0001213900-25-075652.md) | [0.0 d](/filings/0001213900-25-109961.md) | [0.0 d](/filings/0001213900-26-035707.md) | not reported | not reported | not reported | not reported | [176](/filings/0001213900-26-057695.md) | [852](/filings/0001213900-26-089258.md) |
| Net income | $k | [(3,332)](/filings/0001213900-24-098375.md) | [(3,134) d](/filings/0001013762-25-002734.md) | [(3,576)](/filings/0001213900-25-042714.md) | [(3,826)](/filings/0001213900-25-075652.md) | [(3,184)](/filings/0001213900-25-109961.md) | [(3,087) d](/filings/0001213900-26-035707.md) | [(3,616)](/filings/0001213900-26-057695.md) | [(2,769)](/filings/0001213900-26-089258.md) | [(3,339)](/filings/0001213900-25-109961.md) | [(2,832) d](/filings/0001213900-26-035707.md) | [(3,476)](/filings/0001213900-26-057695.md) | [(4,050)](/filings/0001213900-26-089258.md) |
| Diluted EPS | $ per share | [(11.69)](/filings/0001213900-24-098375.md) | not reported | [(10.02)](/filings/0001213900-25-042714.md) | [(8.16)](/filings/0001213900-25-075652.md) | [(3.63)](/filings/0001213900-25-109961.md) | not reported | [1.01](/filings/0001213900-26-057695.md) | [(12.76)](/filings/0001213900-26-089258.md) | [(0.40)](/filings/0001213900-25-109961.md) | not reported | [0.31](/filings/0001213900-26-057695.md) | [(12.35)](/filings/0001213900-26-089258.md) |
| Basic EPS | $ per share | [(11.69)](/filings/0001213900-24-098375.md) | not reported | [(10.02)](/filings/0001213900-25-042714.md) | [(8.16)](/filings/0001213900-25-075652.md) | [(3.63)](/filings/0001213900-25-109961.md) | not reported | [(1.01)](/filings/0001213900-26-057695.md) | [(12.76)](/filings/0001213900-26-089258.md) | [(0.40)](/filings/0001213900-25-109961.md) | not reported | [(0.31)](/filings/0001213900-26-057695.md) | [(12.35)](/filings/0001213900-26-089258.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | period not labelled (2024-05-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [2.4](/filings/0001013762-25-002734.md) | [4.4](/filings/0001213900-24-043085.md) | not reported | [2.0](/filings/0001213900-24-068416.md) | [9.2](/filings/0001213900-24-098375.md) | [6.5](/filings/0001213900-26-035707.md) | [10.3](/filings/0001213900-25-042714.md) | [7.8](/filings/0001213900-25-075652.md) | [3.4](/filings/0001213900-25-109961.md) | [3.8](/filings/0001213900-26-089258.md) | [4.6](/filings/0001213900-26-057695.md) | [1.7](/filings/0001213900-26-089258.md) |
| Current assets | $m | [3.9](/filings/0001013762-25-002734.md) | [6.0](/filings/0001213900-24-043085.md) | not reported | [4.1](/filings/0001213900-24-068416.md) | [11.2](/filings/0001213900-24-098375.md) | [8.2](/filings/0001213900-26-035707.md) | [12.0](/filings/0001213900-25-042714.md) | [9.9](/filings/0001213900-25-075652.md) | [6.5](/filings/0001213900-25-109961.md) | [6.8](/filings/0001213900-26-089258.md) | [7.6](/filings/0001213900-26-057695.md) | [4.8](/filings/0001213900-26-089258.md) |
| Total assets | $m | [6.3](/filings/0001013762-25-002734.md) | [8.0](/filings/0001213900-24-043085.md) | not reported | [6.0](/filings/0001213900-24-068416.md) | [13.0](/filings/0001213900-24-098375.md) | [9.8](/filings/0001213900-26-035707.md) | [13.4](/filings/0001213900-25-042714.md) | [11.1](/filings/0001213900-25-075652.md) | [10.4](/filings/0001213900-25-109961.md) | [10.8](/filings/0001213900-26-089258.md) | [12.8](/filings/0001213900-26-057695.md) | [9.9](/filings/0001213900-26-089258.md) |
| Current liabilities | $m | [3.1](/filings/0001013762-25-002734.md) | [2.3](/filings/0001213900-24-043085.md) | not reported | [3.4](/filings/0001213900-24-068416.md) | [3.2](/filings/0001213900-24-098375.md) | [1.9](/filings/0001213900-26-035707.md) | [2.2](/filings/0001213900-25-042714.md) | [2.6](/filings/0001213900-25-075652.md) | [3.0](/filings/0001213900-25-109961.md) | [3.2](/filings/0001213900-26-089258.md) | [7.4](/filings/0001213900-26-057695.md) | [8.3](/filings/0001213900-26-089258.md) |
| Total liabilities | $m | [5.6](/filings/0001013762-25-002734.md) | [4.4](/filings/0001213900-24-043085.md) | not reported | [5.2](/filings/0001213900-24-068416.md) | [4.8](/filings/0001213900-24-098375.md) | [3.9](/filings/0001213900-26-035707.md) | [4.0](/filings/0001213900-25-042714.md) | [4.4](/filings/0001213900-25-075652.md) | [5.6](/filings/0001213900-25-109961.md) | [5.7](/filings/0001213900-26-089258.md) | [10.9](/filings/0001213900-26-057695.md) | [11.7](/filings/0001213900-26-089258.md) |
| Shareholders' equity | $m | [0.8](/filings/0001213900-26-035707.md) | [3.6](/filings/0001213900-25-075652.md) | [0.8](/filings/0001213900-24-098375.md) | [0.8](/filings/0001213900-25-109961.md) | [8.2](/filings/0001213900-25-109961.md) | [6.0](/filings/0001213900-26-089258.md) | [9.4](/filings/0001213900-26-089258.md) | [6.7](/filings/0001213900-26-089258.md) | [4.8](/filings/0001213900-25-109961.md) | [5.0](/filings/0001213900-26-089258.md) | [1.9](/filings/0001213900-26-089258.md) | [(1.7)](/filings/0001213900-26-089258.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(3,153) d](/filings/0001213900-24-098375.md) | [(2,278) d](/filings/0001013762-25-002734.md) | [(2,338)](/filings/0001213900-25-042714.md) | [(2,420) d](/filings/0001213900-25-075652.md) | [(2,343) d](/filings/0001213900-25-109961.md) | [(2,777) d](/filings/0001213900-26-035707.md) | [(2,483)](/filings/0001213900-26-057695.md) | [(2,214) d](/filings/0001213900-26-089258.md) | [(3,824) d](/filings/0001213900-25-109961.md) | [(2,224) d](/filings/0001213900-26-035707.md) | [(2,960)](/filings/0001213900-26-057695.md) | [(2,758) d](/filings/0001213900-26-089258.md) |
| Capital expenditure | $k | [57.0 d](/filings/0001213900-24-098375.md) | [92.0 d](/filings/0001013762-25-002734.md) | [119](/filings/0001213900-25-042714.md) | [0.0 d](/filings/0001213900-25-075652.md) | [104 d](/filings/0001213900-25-109961.md) | [(37.0) d](/filings/0001213900-26-035707.md) | not reported | not reported | [(111) d](/filings/0001213900-25-109961.md) | [192 d](/filings/0001213900-26-035707.md) | [56.0](/filings/0001213900-26-057695.md) | [172 d](/filings/0001213900-26-089258.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [1.1](/filings/0001213900-23-087015.md) | [1.1](/filings/0001213900-24-043085.md) | [1.3](/filings/0001213900-24-068416.md) | [0.3](/filings/0001213900-24-098375.md) | [0.4](/filings/0001213900-25-042714.md) | [0.5](/filings/0001213900-25-075652.md) | [0.9](/filings/0001213900-25-109961.md) | [3.6](/filings/0001213900-26-057695.md) | [0.2](/filings/0001213900-26-089258.md) | [8.3](/filings/0001213900-25-109961.md) | [11.3](/filings/0001213900-26-057695.md) | [0.3](/filings/0001213900-26-089258.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 667,047 at 2026-08-13, from the cover of the [10-Q filed 2026-08-13](/filings/0001213900-26-089258.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.